Clinical trial of pemetrexed injection combined with cisplatin injection in the treatment of non-small cell lung cancer
10.13699/j.cnki.1001-6821.2018.07.016
- VernacularTitle:培美曲塞注射剂联合顺铂注射剂治疗非小细胞肺癌的临床疗效研究
- Author:
Zheng YUAN
1
;
Zhen LI
;
Yan-Zhen SUN
;
Li-Shuo GUO
;
Yun XU
;
Jian-Min HUANG
Author Information
1. 南阳市中心医院病理科
- Keywords:
pemetrexed injection;
cisplatin injection;
non-small cell lung cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):790-792
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of pemetrexed injection combined with cisplatin injection in the treatment of non-small cell lung cancer.Methods Forty-two patients with non-small cell lung cancer were randomly divided into control group and treatment group with 21 cases per group.Control group was given intravenous infusion of 500 mg · m-2 pemetrexed (day 1).Treatment group were given intravenous infusion of 500 mg · m-2 pemetrexed (day 1) and intravenous infusion of 25 mg · m-2 cisplatin (day 1-3) after 30 min.Two groups were treated for two cycles with 3 weeks per cycle.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of the treatment and control groups were 52.38％ (11 cases/21 cases) and 23.81％ (5 cases/21 cases) with significant difference (P ＜ 0.05).The adverse drug reactions of treatment group were based on fever,which in control group were based on thrombocytopenia,fever and rash.The total incidences of adverse drug reactions in the treatment and control groups were 47.62％ and 57.14％ without significant difference (P ＞ 0.05).Conclusion Pemetrexed injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of non-small cell lung cancer,without increasing the incidence of adverse drug reactions.
